Oppenheimer Asset Management Inc. Trims Stock Holdings in Beigene Ltd (NASDAQ:BGNE)
Oppenheimer Asset Management Inc. reduced its stake in Beigene Ltd (NASDAQ:BGNE) by 13.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,977 shares of the company’s stock after selling 309 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Beigene were worth $245,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of BGNE. Myriad Asset Management Ltd. purchased a new stake in shares of Beigene in the second quarter valued at $70,734,000. New Silk Road Investment PTE Ltd. purchased a new position in Beigene during the second quarter worth about $15,292,000. Geode Capital Management LLC lifted its position in Beigene by 418.8% during the fourth quarter. Geode Capital Management LLC now owns 134,057 shares of the company’s stock worth $18,629,000 after buying an additional 108,218 shares during the period. Matthews International Capital Management LLC lifted its position in Beigene by 28.6% during the second quarter. Matthews International Capital Management LLC now owns 300,303 shares of the company’s stock worth $37,184,000 after buying an additional 66,700 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Beigene by 12.2% during the second quarter. Janus Henderson Group PLC now owns 530,090 shares of the company’s stock worth $65,704,000 after buying an additional 57,466 shares during the period.
Shares of BGNE stock traded up $0.27 during trading hours on Friday, reaching $133.36. The company had a trading volume of 3,877 shares, compared to its average volume of 386,966. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.28 and a current ratio of 6.46. Beigene Ltd has a twelve month low of $105.19 and a twelve month high of $179.57. The company has a market capitalization of $6.05 billion, a P/E ratio of -10.95 and a beta of 1.02. The stock’s fifty day simple moving average is $136.56 and its 200 day simple moving average is $130.77.
In other Beigene news, CMO Jane Huang sold 430 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $124.52, for a total transaction of $53,543.60. Following the transaction, the chief marketing officer now owns 3 shares of the company’s stock, valued at approximately $373.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Xiaodong Wang sold 4,847 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $126.46, for a total value of $612,951.62. Following the transaction, the insider now directly owns 7,611,628 shares in the company, valued at approximately $962,566,476.88. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,365 shares of company stock valued at $4,478,041. 13.40% of the stock is owned by insiders.
Several equities analysts recently weighed in on the company. BidaskClub downgraded Beigene from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 7th. Morgan Stanley dropped their price target on Beigene from $207.00 to $201.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. ValuEngine upgraded Beigene from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Sanford C. Bernstein initiated coverage on Beigene in a research note on Tuesday, June 4th. They set an “outperform” rating and a $201.00 price target for the company. Finally, Macquarie initiated coverage on Beigene in a research note on Friday, July 5th. They set an “underperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $181.28.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
See Also: How does a security become overbought?
Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beigene Ltd (NASDAQ:BGNE).
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.